United States securities and exchange commission logo

                          May 6, 2022

       Luca Santarelli
       Chief Executive Officer
       VectivBio Holding AG
       Aeschenvorstadt 36
       4051 Basel

                                                        Re: VectivBio Holding
Statement on Form F-3
                                                            Filed May 4, 2022
                                                            File No. 333-264653

       Dear Mr. Santarelli:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Daniel
Crawford at 202-551-7767 with any questions.


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Brandon Fenn, Esq.